$0 Co-Pay Program

Rubraca is available at $0 co-pay to 100% of commercially insured patients, regardless of income.


Text-based support

The Clovis4YOU text message support program is a personalized patient program with medication reminders, daily tips, emotional support, and more that can help you throughout treatment.


Share Your Story

You can make a difference for yourself and others by sharing your experiences and perspective.

Understanding genetic mutations and disease

Genetic testing informs your treatment choices

Oncologists often test for BRCA mutations. BRCA genes are some of the most well understood in ovarian cancer, and many therapies were designed to target cancer cells with these specific mutations. Knowing if your tumor has these mutations will help you and your oncologist decide on the best treatment course.
It's also important to know your BRCA status because BRCA genes can be hereditary. Other family members may have the same genetic mutations which can put them at a greater risk for developing breast, ovarian, or prostate cancer.

There are 2 types of BRCA gene mutations


Inherited (also called germline), meaning the gene mutation is passed down from parent to child. Germline mutations are present in every cell in the body, not just in the tumor cells.


Acquired (also called somatic), meaning the gene mutation is not passed down from parent to child, but occurs randomly and can develop at any time. Somatic mutations are only present in the tumor cells.

Genetic testing doesn’t end with BRCA

BRCA mutations were some of the first mutations that helped scientists understand what we now call homologous recombination deficiency, or HRD. When a tumor has HRD, it means the tumor cells are not repairing DNA correctly. This may lead to uncontrolled cancer growth. The tumor cells may have mutations in other genes, known as HR genes. Both BRCA and HR genes can have mutations that contribute to HRD in tumor cells and cancer growth.
Talk icon

That’s why it’s important to ask your oncologist if your tumor cells have a BRCA mutation or HRD.

Did you know?

60% of women with ovarian cancer have tumors with HRD, 20% of those tumors also have BRCA mutations.*
Women graphic Women graphic (mobile)
*Based on 60% of estimated incidence for 2019 from the National Cancer Institute SEER Statistics.

Ask your doctor about an HRD Genetic Test

Mutations in BRCA genes and HR genes lead to the same problem—tumor growth. Knowing your HRD and BRCA status can help inform your treatment decisions.
HRD Graphic HRD genetic (mobile)
Gen image
How is Rubraca
thought to work?
Learn more

We at Clovis Oncology admire the strength and courage of women living with recurrent ovarian cancer, and extend our sincere gratitude to participants of the Rubraca clinical trials.

What is Rubraca used for?

Rubraca is a prescription medicine used for the maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy.

It is not known if Rubraca is safe and effective in children.

What Warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

You should not use Rubraca if:

  • you are pregnant or plan to become pregnant. Rubraca can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with Rubraca
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with Rubraca
    • Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of Rubraca
    • Talk to your healthcare provider about birth control methods that may be right for you
    • Tell your healthcare provider right away if you become pregnant
  • you are breastfeeding or plan to breastfeed. It is not known if Rubraca passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of Rubraca. Talk to your healthcare provider about the best way to feed your baby during this time

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for women in the Rubraca clinical studies were nausea, tiredness/weakness, stomach pain, rash, altered taste, decrease in hemoglobin, abnormal liver or kidney function blood tests, constipation, vomiting, diarrhea, decreased platelet count, upper respiratory tract infection, mouth sores, decreased appetite, shortness of breath, and decrease in white blood cell count.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking, which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1-415-409-7220 (US toll) or 1-844-CLVS-ONC (1-844-258-7662; US toll-free).

Please see full Prescribing Information for Important Safety Information.